U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H12N4O3.Zn
Molecular Weight 289.626
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POLAPREZINC

SMILES

[Zn++].NCCC(=O)[N-][C@@H](CC1=CN=CN1)C([O-])=O

InChI

InChIKey=IGXZLYMCFZHNKW-FJXQXJEOSA-L
InChI=1S/C9H14N4O3.Zn/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6;/h4-5,7H,1-3,10H2,(H3,11,12,13,14,15,16);/q;+2/p-2/t7-;/m0./s1

HIDE SMILES / InChI

Description

Polaprezinc is a zinc-containing molecule and used for the therapy of gastric ulcer. It has been reported that this compound inhibits the induction of TNF-a as well as cellular signaling of TNF-a. Polaprezinc has been shown to exert an anti-oxidant property in a tube experiment and accelerate the healing of gastric ulcer in humans. Polaprezinc inhibited EtOH-induced cytochrome c reduction. Protection by polaprezinc was microscopically associated with the prevention of monolayer disruption. In an animal model of chemotherapy-induced oral mucositis polaprezinc improves the recovery from 5-fluorouracil–induced oral mucositis in hamsters. Polaprezinc ameliorates mucosal ulceration in acetic acid-induced experimental oral mucositis in hamsters. Polaprezinc is potentially useful for prevention of oral mucositis and improvement of quality of life without reducing the tumor response. Polaprezinc is in phase II clinical trial for the treatment of taste disorders.

Originator

Approval Year

2019
334
Targets

Targets

Primary TargetPharmacologyConditionPotency
Heat shock 70 kDa protein
1
Target ID: P34934
Gene ID: NA
Gene Symbol: NA
Target Organism: Sus scrofa (Pig)
Inhibitor
8504
 33.08 µM [IC50]
Agonist
2752
Agonist
2752
Tumor necrosis factor
6
Target ID: P01375
Gene ID: 7124.0
Gene Symbol: TNF
Target Organism: Homo sapiens (Human)
Inhibitor
8504
PubMed

PubMed

TitleDatePubMed
Protective effect of polaprezinc on cadmium-induced injury of lung epithelium.
2019-07-17
Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial.
2019-03
Protective effect of polaprezinc on acute gastric mucosal injury in rats.
2019-01-28
Biological, thermal and mechanical characterization of modified glass ionomer cements: The role of nanohydroxyapatite, ciprofloxacin and zinc l-carnosine.
2019-01-01
Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
2019
Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy.
2018-11
Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review.
2018-08
Prophylactic Effect of Polaprezinc, a Zinc-L-carnosine, Against Chemotherapy-induced Oral Mucositis in Pediatric Patients Undergoing Autologous Stem Cell Transplantation.
2018-08
Effects of polaprezinc on gastric mucosal damage and neurotransmitters in a rat model of chemotherapy-induced vomiting.
2018-06
Insufficient evidence for interventions to prevent dry mouth and salivary gland dysfunction post head and neck radiotherapy.
2018-03-23
Zinc, Carnosine, and Neurodegenerative Diseases.
2018-01-29
Zinc deficiency anaemia in haemodialysis patients: Often overlooked but a treatable cause of anaemia.
2017-12
Zinc-L-Carnosine Complex (Polaprezinc) for the Treatment of Binge Eating: Three Case Reports.
2017-12
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
2017-12
Effect of polaprezinc on experimental corrosive esophageal burns in rats.
2017-11-01
Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma.
2017-10
Zinc L-carnosine suppresses inflammatory responses in lipopolysaccharide-induced RAW 264.7 murine macrophages cell line via activation of Nrf2/HO-1 signaling pathway.
2017-10
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
2017-07-31
Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?
2017-01-18
Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
2017
Patents

Patents

EP 303380
1
US 4981846
1
Name Type Language
POLAPREZINC
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
polaprezinc [INN]
Preferred Name English
Z-103
Code English
L-HISTIDINE, N-.BETA.-ALANYL-, ZINC COMPLEX
Common Name English
POLAPREZINC [MI]
Common Name English
.BETA.-ALANYL-L-HISTIDINATO ZINC
Common Name English
POLAPREZINC [MART.]
Common Name English
Z 103
Code English
ZINC L-CARNOSINE
Common Name English
ZINC, (.BETA.-ALANYL-.KAPPA.N-L-HISTIDINATO(2-)-.KAPPA.N,.KAPPA.O)-
Common Name English
PROMAC
Common Name English
ZINC CARNOSINE
Common Name English
Polaprezinc [WHO-DD]
Common Name English
POLAPREZINC [JAN]
Common Name English
ZINC, (N-.BETA.-ALANYL-L-HISTIDINATO(2-)-N,NN,O.ALPHA.)-
Common Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
NCI_THESAURUS C29701
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
NCI_THESAURUS C26170
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
DSLD 4102 (Number of products:4)
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
Code System Code Type Description
SMS_ID
100000081935
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
FDA UNII
0WA1B15A1Z
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
RXCUI
2179843
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
INN
6917
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
PUBCHEM
9817450
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
MERCK INDEX
m8939
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB09221
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
DRUG CENTRAL
4756
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
MESH
C061957
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
CAS
107667-60-7
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID7048615
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
EVMPD
SUB09963MIG
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
NCI_THESAURUS
C118371
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
DAILYMED
0WA1B15A1Z
Created by admin on Mon Mar 31 21:41:48 GMT 2025 , Edited by admin on Mon Mar 31 21:41:48 GMT 2025
PRIMARY
SUBSTANCE RECORD
Structure of POLAPREZINC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966